Insurance Appeal Letter Sample for Denied Claims (3 Real Examples)
May 8, 2026
14 min read
AppealGen Research Team
The difference between a successful appeal and a rejected one usually comes down to one thing: whether the letter directly addresses the specific reason for denial with clinical evidence. These three samples show you exactly how to do that — for the three most common denial types.
Each sample below is built around a specific denial reason. Before adapting one to your case, read your denial letter carefully and identify the exact reason cited. Then use the sample that matches — not the one that sounds most persuasive.
💡 Important
A generic appeal letter that doesn’t address your specific denial reason will almost always be rejected. Insurance reviewers are trained to look for a direct rebuttal of the stated rationale. These samples are structured to provide exactly that.
83%
of prior authorization appeals are overturned when properly documented — yet fewer than 1 in 100 denied patients ever files a formal appeal.
KFF Analysis of ACA Marketplace Denials, 2023
Sample 1: Medical Necessity Denial
This is the most common denial type. The insurer claims the treatment is “not medically necessary” — typically based on a set of administrative criteria applied without a physician reviewing your actual records. Your rebuttal must present objective clinical evidence and demonstrate that you meet established medical guidelines.
When to use this sample
Your denial letter says “not medically necessary” or “does not meet clinical criteria”
The denial references plan guidelines or LCD (Local Coverage Determination) criteria
Your physician ordered the treatment and you have supporting clinical records
Sample 1 of 3Medical Necessity Denial
Marcus Williams
Date of Birth: 07/22/1975
Member ID: UHC-882341-MW
Policy Number: PPO-UHC-2026-8823
May 8, 2026
UnitedHealthcare
Appeals and Grievances Department
P.O. Box 30432
Salt Lake City, UT 84130
Re: Formal Appeal of Denial for Continuous Glucose Monitor (CPT: A9278)
Claim #: UHC-2026-0412-88231
Date of Service: April 12, 2026
Dear Appeals Review Committee,
I am writing to formally appeal the denial of coverage for a Continuous Glucose Monitor (CGM) system (CPT: A9278), prescribed by my treating physician, Dr. Priya Nambiar, MD, Board-Certified Endocrinologist at Midwest Diabetes Care Center. The denial dated April 19, 2026 states this device is “not medically necessary.” This determination is inconsistent with established clinical guidelines and my documented medical history.
Clinical Background and Diagnosis
I have been diagnosed with Type 1 Diabetes Mellitus (ICD-10: E10.65) for 22 years. My condition is characterized by significant glycemic variability, including nocturnal hypoglycemic episodes occurring 3–5 times per week as documented in my medical records from January through March 2026. My most recent HbA1c is 8.4%, reflecting inadequate glycemic control despite intensive management.
Objective Clinical Evidence
My medical record documents the following objective findings supporting medical necessity:
• Documented hypoglycemic episodes: 14 confirmed episodes below 54 mg/dL over the past 90 days (January–March 2026 glucose log, attached)
• Hypoglycemia unawareness: Dr. Nambiar’s examination notes confirm impaired hypoglycemia awareness, placing me at high risk for severe hypoglycemic events
• Current regimen: Multiple Daily Injections (MDI) with insulin glargine and lispro — a regimen that requires frequent glucose monitoring to prevent dangerous excursions
• Emergency visit: One hypoglycemia-related ER visit on February 8, 2026 (ER records attached)
Treatment History
I have used standard fingerstick glucose monitoring (7–10 checks per day) for the past 22 years. Despite this frequency, nocturnal hypoglycemia continues due to the inability of fingerstick monitoring to detect glucose trends while asleep. A CGM provides real-time alerts that fingerstick monitoring cannot — this distinction is not a preference but a clinical necessity for patients with hypoglycemia unawareness.
Rebuttal of Denial Rationale
The denial states this device does not meet medical necessity criteria. However, the American Diabetes Association Standards of Medical Care in Diabetes (2026) specifically recommends CGM for adults with Type 1 diabetes on MDI regimens, particularly those with hypoglycemia unawareness. Additionally, CMS coverage criteria for CGMs — which many commercial plans align with — include patients with frequent hypoglycemia, which my records document extensively.
The denial appears to have been made without review of my complete clinical record. I respectfully request that a physician reviewer with endocrinology expertise conduct a full review of the attached documentation before issuing a final determination.
Request for Action
I request immediate approval of coverage for the Continuous Glucose Monitor (CPT: A9278) as prescribed by Dr. Nambiar. I am attaching the following:
1. Letter of medical necessity from Dr. Priya Nambiar, MD (Endocrinology)
2. 90-day glucose log documenting hypoglycemic episodes (January–March 2026)
3. Emergency department records, February 8, 2026
4. ADA Standards of Care 2026 — relevant section on CGM indications
5. History and physical examination notes confirming hypoglycemia unawareness
I am available to provide any additional information. Dr. Nambiar has also indicated her availability for a peer-to-peer review — please contact her office at (312) 555-0847.
Sincerely,
______________________________
Marcus Williams
Member ID: UHC-882341-MW
Generate Your Own Medical Necessity Appeal
AppealGen builds a letter tailored to your specific diagnosis, clinical evidence, and denial reason — in under 10 minutes.
Prior authorization denials come in two forms: the authorization was denied before treatment (pre-service), or treatment occurred without authorization and the claim was denied after (post-service). Both are appealable, but the strategy differs slightly. This sample addresses the most common scenario: a pre-service denial where authorization was requested and rejected.
When to use this sample
Your denial cites “no prior authorization” or “authorization not obtained”
Your physician requested authorization and it was denied
The treatment is established medical practice for your diagnosis
Sample 2 of 3Prior Authorization Denial
Jennifer Okafor
Date of Birth: 11/03/1988
Member ID: AET-556721-JO
Policy Number: HMO-AET-2026-5567
May 8, 2026
Aetna Health Insurance
Member Appeals Department
P.O. Box 14079
Lexington, KY 40512
Re: Formal Appeal of Prior Authorization Denial for Dupilumab (Dupixent) Injection
Authorization Request #: AET-PA-2026-0389
Date of Request: April 22, 2026
Dear Aetna Appeals Review Committee,
I am writing to formally appeal the denial of prior authorization for Dupilumab (Dupixent) 300mg/2mL subcutaneous injection, prescribed by Dr. Amara Osei, MD, Board-Certified Dermatologist at Atlanta Dermatology Associates. The denial dated April 28, 2026 states that this medication “does not meet criteria for prior authorization.” I respectfully dispute this determination.
Clinical Background
I have a confirmed diagnosis of moderate-to-severe atopic dermatitis (ICD-10: L20.89) affecting greater than 40% of my body surface area, as documented in Dr. Osei’s clinical notes. My condition has been progressive and treatment-resistant for the past four years, significantly impacting my ability to work, sleep, and perform daily activities. I have been unable to wear professional attire due to visible skin involvement, affecting my employment as a litigation attorney.
Step Therapy Requirements — Documented Completion
I understand that Aetna’s clinical criteria for Dupilumab require documentation of inadequate response to conventional therapies. I have completed step therapy as required:
• Topical corticosteroids (high-potency): Used continuously for 3 years. Initial partial response followed by tachyphylaxis and skin atrophy at application sites (documented January 2023 – December 2025)
• Topical calcineurin inhibitors (tacrolimus 0.1%): 6-month trial completed June 2024. Inadequate response with EASI score remaining at 32 (severe range) at conclusion of trial
• Cyclosporine: 4-month systemic trial completed October 2025. Discontinued due to nephrotoxicity (creatinine rise to 1.6 mg/dL) before adequate therapeutic response was achieved
• Methotrexate: 5-month trial completed March 2026. Inadequate response (EASI score 28 at end of trial) with dose-limiting hepatotoxicity
This represents exhaustion of all conventional immunosuppressive options available for atopic dermatitis. Dupilumab is the appropriate next-line biologic therapy per AAD guidelines.
Clinical Guideline Support
The American Academy of Dermatology guidelines recommend Dupilumab for adults with moderate-to-severe atopic dermatitis who have had inadequate response to topical therapies and systemic immunosuppressants — precisely my clinical situation. Dupilumab has FDA approval for this indication and has established safety and efficacy across multiple phase III trials.
Rebuttal of Denial Rationale
The denial does not specify which criterion was not met. I am requesting, as is my right under ERISA, a specific written explanation of which clinical criteria were used to evaluate this request and which specific criterion was not satisfied. In the absence of that specification, I assert that all applicable criteria have been met based on the documentation provided with this appeal.
Request for Action
I request approval of prior authorization for Dupilumab (Dupixent) 300mg/2mL as prescribed by Dr. Osei. Attached documentation includes:
1. Letter of medical necessity from Dr. Amara Osei, MD (Dermatology)
2. Step therapy documentation — all prior treatment records with outcomes
3. EASI scoring documentation across all treatment trials
4. Laboratory results documenting toxicity from cyclosporine and methotrexate
5. AAD clinical guideline excerpt supporting Dupilumab as appropriate next-line therapy
Dr. Osei is available for peer-to-peer review. Please contact her office at (404) 555-0233.
Sincerely,
______________________________
Jennifer Okafor
Member ID: AET-556721-JO
Sample 3: Out-of-Network Denial
Out-of-network denials require a different argument. Rather than proving medical necessity, you need to establish either that no adequate in-network option exists, that continuity of care requires staying with your current provider, or that the service was provided in an emergency. This sample addresses the most winnable scenario: lack of in-network coverage for a specialized service.
When to use this sample
Your denial cites “out-of-network provider” or “non-participating provider”
No in-network provider with equivalent expertise is available in your area
You have a specialized condition requiring a specific type of expertise
Sample 3 of 3Out-of-Network Denial
Rachel Thornton
Date of Birth: 09/14/1979
Member ID: BCBS-774432-RT
Policy Number: PPO-BCBS-2026-7744
May 8, 2026
Blue Cross Blue Shield of Texas
Member Appeals Department
P.O. Box 660044
Dallas, TX 75266
Re: Formal Appeal of Out-of-Network Denial for Surgical Services
Claim #: BCBS-2026-0228-77443
Provider: Dr. James Holloway, MD — Austin Neurosurgery Center
Date of Service: February 28, 2026
Dear Blue Cross Blue Shield Appeals Review Committee,
I am writing to formally appeal the denial of coverage for surgical services rendered by Dr. James Holloway, MD, FAANS, at Austin Neurosurgery Center on February 28, 2026. The denial cites Dr. Holloway as an out-of-network provider. I respectfully appeal this determination on the grounds of network inadequacy and the medical necessity of accessing this specific specialist.
Background
I have a confirmed diagnosis of a cervical spinal arteriovenous malformation (AVM) at C3–C4 (ICD-10: Q28.1), a rare vascular anomaly affecting fewer than 1 in 100,000 individuals. Following diagnosis in January 2026, my neurologist, Dr. Sarah Chen, MD at Dell Seton Medical Center, referred me to Dr. Holloway as the only neurosurgeon in Texas with documented fellowship training and operative experience in spinal AVM resection.
Network Adequacy Failure
I made good-faith efforts to identify an in-network provider capable of performing spinal AVM resection prior to scheduling with Dr. Holloway. My documented attempts include:
• January 15, 2026: Called BCBS member services requesting referral to in-network neurosurgeons who perform spinal AVM surgery. Was provided a list of 4 in-network neurosurgeons in my area.
• January 16–20, 2026: Contacted all 4 in-network neurosurgeons. None perform spinal AVM resection — all 4 confirmed in writing they do not have the required subspecialty training. (Letters attached.)
• January 22, 2026: Dr. Chen confirmed in writing that Dr. Holloway is the appropriate specialist for this procedure and that delaying treatment to seek alternative providers presented unacceptable neurological risk.
Under the ACA’s network adequacy standards and Texas Insurance Code Section 1301, health insurers are required to provide adequate access to covered services. When no in-network provider can perform a covered service, the insurer is obligated to provide coverage at in-network cost-sharing rates or authorize an out-of-network exception.
Medical Necessity of Urgency
Dr. Chen’s records document that the AVM presented with active hemorrhagic risk. Delaying surgery beyond 60 days from diagnosis carried an estimated 8–12% risk of hemorrhage resulting in permanent neurological deficit or death, per the medical literature Dr. Chen cited in her referral note. This timeline made searching for additional out-of-network alternatives clinically untenable.
Request for Action
I request that Blue Cross Blue Shield of Texas reprocess this claim at in-network benefit levels, given the documented failure of network adequacy for this subspecialty service. Alternatively, I request retroactive out-of-network exception authorization. Attached documentation includes:
1. Written confirmation from all 4 in-network neurosurgeons that they do not perform spinal AVM resection
2. Referral letter from Dr. Sarah Chen, MD documenting medical necessity and urgency
3. Dr. Holloway’s operative report and credentials (fellowship in cerebrovascular and spinal vascular surgery)
4. Texas Insurance Code Section 1301 network adequacy provisions
5. ACA network adequacy standards applicable to this plan
I am prepared to escalate to the Texas Department of Insurance if network adequacy requirements are found to have been violated. Please respond within the timeframe required by Texas state law.
Sincerely,
______________________________
Rachel Thornton
Member ID: BCBS-774432-RT
Get a Letter Built for Your Specific Case
These samples show the structure — but your appeal needs your clinical details, your denial reason, and your physician’s specific findings. AppealGen builds that letter in 10 minutes.
Using a sample letter without adapting it is one of the most common mistakes patients make. Insurance reviewers recognize generic letters immediately — and a letter that doesn’t reflect your specific clinical situation carries almost no weight.
Step 1: Match the denial reason exactly
Copy the exact language from your denial letter into the Re: line and into the rebuttal section. If your denial says “service does not meet criteria under Plan Section 4.2(b),” reference that exact section in your response. Specificity signals that you have read and understood the denial.
Step 2: Replace all clinical details with your own
Every diagnosis code, symptom description, duration, test result, and treatment history must be yours — not the sample patient’s. Review your medical records before writing and pull specific numbers: HbA1c values, pain scores, EASI scores, creatinine levels, documented episode frequencies. Objective data is far more persuasive than narrative descriptions.
Step 3: Get a letter from your physician
None of these samples work without a supporting physician letter. Your doctor needs to provide a written statement that is specific to your case — not a pre-printed form. The letter should state the diagnosis, the clinical rationale for the treatment, why alternatives were inadequate or inappropriate, and the consequences of continued denial.
Step 4: Reference clinical guidelines
Each sample references a professional society guideline (ADA, AAD) or regulatory framework (ACA, ERISA, state insurance code). Find the guideline that applies to your treatment and diagnosis. Your physician can usually help identify this. A specific citation — “per ADA Standards 2026, Section 7.3” — is far more effective than saying “this is standard of care.”
What Makes These Letters Work
These three samples share five structural characteristics that distinguish effective appeal letters from rejected ones.
1. They open with the specific denial reason
Every letter immediately identifies the exact denial cited and states it is being appealed. Reviewers know from the first paragraph what they are evaluating and what standard they must apply.
2. They present objective evidence, not subjective experience
Notice that each letter leads with documented clinical findings — lab values, scores, episode counts, test results — not descriptions of suffering. Insurance reviewers respond to data, not narratives.
3. They document treatment history exhaustively
Each sample shows a clear progression through prior treatments with specific durations and documented outcomes. This is essential for medical necessity and prior authorization appeals — it demonstrates that the denied treatment is not the first resort but the appropriate next step.
4. They cite a specific guideline or regulatory provision
A reviewer who upholds a denial despite a specific clinical guideline citation is making a decision that can be challenged externally. Citations create accountability that vague assertions do not.
5. They request peer-to-peer review
Every letter offers the treating physician for a peer-to-peer discussion. This request has two effects: it signals that a real physician stands behind the treatment decision, and it creates an obligation for the insurance company’s reviewer to engage with the clinical argument rather than simply applying an administrative checklist.
→ Next Step
If your appeal is denied internally, you are entitled to an external review by an independent organization. External reviews overturn insurer decisions in 40–60% of cases and are binding on the insurance company. See our Patient Rights guide for full details on the external review process.
Skip the Template. Build Your Appeal.
AppealGen generates a complete, evidence-based appeal letter tailored to your denial reason, diagnosis, and clinical history — not a sample you adapt yourself. Free to start.